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Abstract
Background: Retroviral elements are pervasively transcribed and dynamically regulated during development. While
multiple histone- and DNA-modifying enzymes have broadly been associated with their global silencing, little is
known about how the many diverse retroviral families are each selectively recognized.
Results: Here we show that the zinc finger protein Krüppel-like Factor 3 (KLF3) specifically silences transcription
from the ORR1A0 long terminal repeat in murine fetal and adult erythroid cells. In the absence of KLF3, we detect
widespread transcription from ORR1A0 elements driven by the master erythroid regulator KLF1. In several instances
these aberrant transcripts are spliced to downstream genic exons. One such chimeric transcript produces a novel,
dominant negative isoform of PU.1 that can induce erythroid differentiation.
Conclusions: We propose that KLF3 ensures the integrity of the murine erythroid transcriptome through the
selective repression of a particular retroelement and is likely one of multiple sequence-specific factors that
cooperate to achieve global silencing.
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Background
Transposable elements (TEs) are mobile segments of
DNA that have integrated and spread in eukaryotic
genomes. They constitute a substantial portion of the
mouse and human genomes (approximately 39% and
46%, respectively [1]), and have been a major driving
force in evolution [2]. In mammals, the vast majority of
TEs are retrotransposons: genetic elements that have in-
tegrated into host DNA following reverse transcription
of an RNA template. Broadly, retrotransposons fall into
two categories: those that contain long terminal repeats
(LTRs) and are termed endogenous retroviruses (ERVs);
and those that lack LTRs, namely, long and short inter-
spersed elements (LINES and SINES).
The expansion of TEs has played an important role in
shaping eukaryotic genomes, in part by enabling gen-
omic shuffling by non-allelic homologous recombination
but also by their capacity to remodel gene regulatory
networks [3-7]. Retroviral LTRs, for instance, harbor nu-
merous, functional regulatory elements required for the
initiation and control of transcription and can thus pro-
foundly alter the expression of proximal genes [8,9].
Furthermore, because the many distinct classes of retro-
virus differ in the regulatory sequences contained within
their LTRs, they have proven highly versatile in rewiring
diverse transcriptional programs. Indeed, throughout
mammalian evolution, the spread and proliferation of
retroelements have redistributed binding sites for a
number of transcriptional regulators including the pluri-
potency factors OCT4 and NANOG [5], the insulator
protein CTCF [4-6], the neural repressor NRSF/REST
[10], the tumour suppressor p53 [11], and others [12].
Analogously, expansion of the MER20 and RLTR13D5
transposable elements, which promote endometrial and
trophoblast expression, have been postulated to have en-
abled the placental transcription of genes critical to the
evolutionary development of pregnancy [13,14].
Not only do retrotransposons provide regulatory mod-
ules that influence nearby genes, they can also directly
provide promoters that dictate transcriptional initiation.
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A notable example of this is the murine Agouti viable
yellow (Avy) allele, in which an upstream intra-cisternal
A particle (IAP) retrotransposon functions as a constitu-
tively active promoter that drives ectopic expression of
Agouti, resulting in yellow fur, obesity, and increased
susceptibility to tumorigenesis [15,16]. The prevalence of
this phenomenon, whereby retrotransposons serve as al-
ternative promoters, has recently been revealed follow-
ing the advent of high-throughput RNA sequencing and
shown to occur primarily in embryonic cells but also to
some extent in adult tissues [17]. During early embry-
onic development in particular, up to 20% of the tran-
scriptome has been shown to initiate from within
retrotransposons [17,18]. These retroelements frequently
function as alternative promoters and show a propensity
for tissue-specific activity, more so in fact than non-
retrotransposon promoters [17]. In many instances,
these retrotransposons have been co-opted by the host
by exonization and they are transcribed and spliced to
downstream genic exons [17,19,20]. The resulting
chimeric transcripts thus potentially encode isoform var-
iants with spatio- or temporally-restricted expression
profiles [21]. Indeed, a recent study of the Drosophila
melanogaster transcriptome has revealed that several
hundred LTR retrotransposons serve as promoters of
annotated genes throughout development, exhibiting
specific expression profiles depending on the different
regulatory modules they carry [22].
However, while there are many reported instances of
TEs being co-opted by the host for various biological
functions, genomic integration of TEs can also be dele-
terious [23-25]. For instance, Hodgkin’s lymphoma has
been shown to arise from aberrant transcription of the
colony-stimulating factor 1 receptor (CSF1R) gene driven
by an internal LTR element known as THE1B [26].
Accordingly, higher eukaryotes have developed nume-
rous defence mechanisms to silence TEs, typically in-
volving DNA methylation and/or histone modification
[27-29]. This silencing largely occurs early in embryonic
development and is dependent on epigenetic modifiers
including: DNA methyltransferases (DNMTs) [27,30];
histone modifying enzymes such as the demethylase
LSD1/KDM1A, the deacetylase HDAC1, and the methyl-
transferases SETDB1 and G9A [31-35]; and Polycomb
Group proteins [36]. Ablation of these factors in embry-
onic stem cells results in widespread de-repression of
retrotransposon-derived transcripts.
However, while silencing of retroelements is broadly
carried out by these epigenetic modifiers, little is known
about the underlying mechanisms by which the diverse
classes of retroelements are each specifically recognized
[28]. Indeed the lack of sequence similarity between un-
related retroviral families suggests the existence of mul-
tiple recognition factors that participate in the silencing
of retroelements. An accumulating body of evidence has
pointed towards the possible role of DNA binding, tan-
dem zinc finger proteins in providing this specificity.
Thomas and Schneider have proposed a model of co-
evolution between retroelements and C2H2 zinc finger
proteins based on striking correlations of their expan-
sion throughout vertebrate genomes [37]. This model
followed from the discovery that the Krüppel-associated
box (KRAB)-zinc finger protein ZFP809 binds and re-
presses a large number of retroelements in mouse em-
bryonic stem cells [38]. ZFP809 achieves this through
the recruitment of the corepressor TRIM28 (also known
as KRAB-associated protein 1, KAP1). TRIM28 in turn
silences ERVs through SETDB1 mediated trimethylation
of H3K9 [31,39,40].
The Krüppel-like factors (KLFs) are a family of DNA
binding, zinc finger transcription factors [41]. They lack
a KRAB domain and are characterized by a set of three
tandem C2H2 zinc fingers at their C-termini that confer
specificity towards CACCC-like and GC-rich sequences
in regulatory elements [42]. While the DNA binding
domain is highly conserved within the family, the
N-terminal regulatory domains vary considerably such
that the different KLFs recruit an assortment of co-
regulators to activate or repress genes [43].
The founding member of the family, KLF1, is an
erythroid-specific transcriptional activator that drives
the expression of genes required for red blood cell mat-
uration [44]. One such gene is that encoding the related
family member KLF3 [45]. KLF3 and KLF1 recognize
similar sequences of DNA that adhere to the consensus
5′-NCN CNC CCN-3′ [42,46]. However, unlike KLF1,
KLF3 is a transcriptional repressor that recruits the
co-repressor C-terminal binding protein (CTBP) [47].
CTBP forms part of a large repressor complex that
includes the histone deacetylases HDAC1 and HDAC2,
the histone methyltransferases EHMT1 and G9A/
EHMT2, and the lysine-specific demethylase LSD1/
KDM1A [48]. KLF1 and KLF3 exhibit opposing activities
at a number of genes in erythroid cells and serve to fine-
tune their expression during erythropoiesis [49,50]. Ac-
cordingly, loss of either factor disrupts this balance. Klf1
null mice die of severe anemia in utero while mice lack-
ing KLF3, though viable, exhibit erythroid defects in
both fetal and adult tissues [49,51].
Here, we have further explored the interplay between
KLF1 and KLF3 in regulating the erythroid transcrip-
tome. We find that KLF1 activates, while KLF3 re-
presses, transcription from a specific family of LTR
elements known as ORR1A0. Ablation of KLF3 results in
widespread, de-repressed transcription from these LTRs
in erythroid cells. Because the ORR1A0 element contains
an intact splice donor site, these transcripts are spliced
to exons of the genes in which they reside. We show
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that for the spleen focus forming virus proviral integra-
tion 1 (Sfpi1) gene, an ORR1A0-driven transcript is
translated into a truncated variant of PU.1 which ex-
hibits dominant negative activity and can functionally
promote erythroid differentiation. These results suggest
that KLF3 ensures normal murine erythropoiesis by pre-
venting aberrant, chimeric transcription driven from
ORR1A0 LTRs by KLF1.
Results
Increased expression of downstream Pu.1 exons in
erythroid cells in the absence of KLF3
We recently identified a number of KLF3 target genes
via microarray analysis of Klf3−/− TER119+ (erythroid)
fetal liver cells at embryonic day E14.5 [49]. These genes
were predominantly de-repressed in Klf3 null tissue,
consistent with KLF3 being a repressor of transcription.
One of the most highly de-repressed genes was that en-
coding the key hematopoietic regulator PU.1/SFPI1,
hereafter referred to as PU.1.
We first sought to validate the upregulation of Pu.1
expression in Klf3−/− cells by quantitative real-time RT-
PCR. Initial experiments, using primers that span the
exon 2/3 junction of Pu.1, did not recapitulate the
microarray results (Figure 1A). Unexpectedly, Pu.1 mRNA
was detected at similar levels in Klf3+/+, Klf3+/−, and
Klf3−/− Ter119+ E14.5 fetal liver cells. To resolve this dis-
crepancy, we analyzed the individual probe intensities
across the Pu.1 locus from the microarray data. The mur-
ine Pu.1 gene comprises five exons and of these, exons
2 to 5 are represented by probes on the arrays. Expression
of only exons 3 to 5 of Pu.1 was found to be higher in
Klf3−/− compared to Klf3+/+ tissue; however, expression of
exon 2 was unchanged (Figure 1B). Real-time RT-PCR
using primers specific for the exon 3/4 and exon 4/5
boundaries of Pu.1 (Figure 1C, D) confirmed that indeed,
exons 3 to 5 exhibit upregulated expression in Klf3−/− cells
while exon 2 does not (Figure 1A).
An ORR1A0 LTR element serves as an alternative
promoter in the Pu.1 locus in the absence of KLF3
The upregulated expression of exons towards the 3′ end
of Pu.1 raised the possibility that an alternative, internal
promoter was driving transcription from the locus and
that this promoter is repressed by KLF3. To investigate
this, we conducted 5′ RACE on mRNA from Klf3+/+ and
Klf3−/− Ter119+ fetal liver cells using a reverse primer
specific for exon 3 of Pu.1. While electrophoretic
Figure 1 Transcripts containing exons towards the 3′ end of Pu.1 are upregulated in Klf3−/− E14.5 TER119+ fetal liver cells. (A, C, D)
Transcript levels in Klf3+/+ (WT, n = 2), Klf3+/− (HET, n = 3), and Klf3−/− (KO, n = 3) cells were determined by quantitative real-time RT-PCR using
forward and reverse primer combinations specific for exons 2 and 3 (A), exons 3 and 4 (C), or exons 4 and 5 (D) of Pu.1. Values have been normalized
to 18S rRNA levels and in each instance the Klf3+/+ sample has been set to 1.0. Error bars represent standard error of the mean. *, P < 0.02 compared
to both Klf3+/+ and Klf3+/− (Student’s two-tailed t-test). (B) Positions of microarray probes across the Pu.1 gene and their relative intensities in Klf3−/−
compared to Klf3+/+ samples. Exons are displayed as blue boxes and are widened to denote the coding region. Schematic is not to scale.
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separation of RACE products revealed a common tran-
script in both samples (an approximately 420 bp band),
a smaller transcript (226 bp) was found in the Klf3−/−
sample (Figure 2A). Sequencing of the two RACE prod-
ucts revealed that the larger band corresponds to exons
1 to 3 of a typical Pu.1 transcript (GenBank:NM_011355).
The shorter transcript, however, was found to contain
exon 3 of Pu.1 preceded by a novel sequence (shown in
bold in Figure 2B). This sequence maps to intron 2 of
Pu.1 and represents an alternative leader exon, hereby
termed exon 2b, which is spliced to exon 3 and which
has not been documented previously, to our knowledge
(Figure 2C). Hereafter, we refer to this novel transcript
as Pu.2.
Figure 2 A novel, internal Pu.1 promoter resides within an ORR1A0 LTR element and is repressed by KLF3. (A) RNA from Klf3+/+ (WT)
and Klf3−/− (KO) TER119+ fetal liver cells was subjected to 5′ RACE using a reverse primer specific for exon 3 of Pu.1 and analyzed by agarose gel
electrophoresis. The smaller band in the Klf3 KO lane was sequenced and found to contain a novel exon (exon 2b). (B) The sequence of the
ORR1A0 LTR, in which Pu.1 exon 2b is shown in bold. Sequences which fit the KLF binding consensus 5′-NCN CNC CCN-3′ are boxed, and the
TATA box at −30 is underlined. (C) Schematic of the murine Pu.1 locus showing the position of exon 2b. Exons are represented by blue boxes,
transcription start sites by arrowheads and splicing events by broken lines. Start points of translation (ATGs) for the two alternative transcripts are
also shown. (D) Real-time RT-PCR quantification revealing that transcripts containing exon 2b spliced to exon 3 of Pu.1 (that is, Pu.2 transcripts)
are upregulated in Klf3−/− TER119+ E14.5 fetal liver cells compared to Klf3+/− (HET) and Klf3+/+. Values have been normalized to 18S rRNA and
the Klf3+/+ sample has been set to 1.0. n = 3 for each genotype. **, P <0.005 compared to both Klf3+/+ and Klf3+/− (Student’s two-tailed t-test).
(E) ChIPs were performed on Klf3+/+ and Klf3−/− E14.5 fetal livers (n = 2 or 3 of each genotype per IP). Data are represented as the fold-change
enrichment in Klf3−/− cells compared to Klf3+/+. The Fam132a and Klf8 promoters have been included as positive controls while Serpina9, Gapdh,
and MyoD are negative control regions. *, P <0.05 compared to Gapdh (Student’s one-tailed t-test). In (D and E), error bars represent standard
error of the mean.
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Searches using the RepeatMasker program showed
that exon 2b lies within a 343 bp long terminal repeat
(LTR) element, named ORR1A0, belonging to the
MaLR (mammalian apparent LTR retrotransposon) fam-
ily (Figure 2B) [52]. The ORR1A0 element in the murine
Pu.1 locus contains several hallmarks of a eukaryotic
core promoter including a TATA box at −30, an initiator
sequence (5′-TCAGTY-3′) at the TSS and a downstream
promoter element around +30 [53]. In addition, it con-
tains several motifs fitting the KLF DNA-binding con-
sensus 5′-NCN CNC CCN-3′ (Figure 2B).
In order to verify that this novel Pu.2 transcript is
de-repressed in erythroid cells lacking KLF3, we per-
formed real-time RT-PCR on Klf3+/+, Klf3+/− and Klf3−/−
Ter119+ E14.5 fetal liver RNA using a forward primer
specific for exon 2b and a reverse primer targeting exon
3 of Pu.1. Indeed, significant up-regulation of the Pu.2
transcript (>140-fold) was observed in Klf3−/− compared
to Klf3+/+ and Klf3+/− samples (Figure 2D). While this
transcript was not amplified from wild-type tissue by
5′ RACE (Figure 2A), we detected low amounts of it in
wild-type and Klf3+/− tissue by RT-PCR. In adult Klf3−/−
mice, we observed marked upregulation of this chimeric
transcript in erythroid organs (spleen and bone marrow)
(Additional file 1: Figure S1A). In contrast, canonical
Pu.1 mRNA was unaltered in these and other tissues ex-
amined (Additional file 1: Figure S1B).
KLF3 can repress transcription by recruiting CTBP,
a co-repressor that silences genes through a number
of different histone-modifying enzymes. We therefore
analyzed a series of histone marks around the Pu.2
ORR1A0 promoter in Klf3−/− compared to Klf3+/+
E14.5 fetal liver cells (Figure 2E). In particular, we
observed a marked increase specifically of histone 3
lysine 4 tri-methylation (H3K4me3) in Klf3−/− cells at
the ORR1A0 promoter (approximately 12-fold). We
found that this mark was also increased at the pro-
moters of previously validated KLF3 target genes
such as Klf8 [50] and Fam132a/adipolin [49,54]
(Figure 2E). H3K4me3 is a mark typically found at
actively transcribed promoters [55]. Moreover, loss of
this mark, rather than the acquisition of repressive
modifications, has been reported during the develop-
mental silencing of retroelements [18]. In addition,
the Pu.2 promoter displayed only a moderate level of
H3K9me3 in wild-type cells (Additional file 2: Figure
S2). This was not appreciably altered in Klf3−/− cells,
suggesting that H3K9 tri-methylation is not the
primary mechanism through which KLF3 silences
transcription at this locus. Together, these results
indicate that the ORR1A0 element is a functional,
alternative promoter for the Pu.1 gene in erythroid
cells and is highly de-repressed in the absence of
KLF3.
KLF1 and KLF3 can bind to the CACCC-like boxes in
the ORR1A0 LTR and activate and repress transcription,
respectively
We next examined by electrophoretic mobility shift
assay (EMSA) whether one or more of the four 5′-NCN
CNC CCN-3′ sites in the ORR1A0 promoter are recog-
nized by KLF3. Indeed, KLF3 was found to bind strongly
to the two sites most distal to the TSS and weakly to the
third CACCC-box (Figure 3A, B). We next assessed
whether the related family member KLF1 also binds to
these sites. KLF1 is highly expressed in erythroid cells
and has a similar DNA-binding specificity to KLF3, such
that the two proteins co-regulate overlapping genes
in vivo [46,49]. We found that like KLF3, KLF1 binds to
the two 5′ most sites (Figure 3C). No detectable binding
was observed for the CACCC boxes closest to the TSS
(Figure 3D).
Having established that both KLF1 and KLF3 can bind
to motifs present in the ORR1A0 element, we next
assessed whether they can functionally regulate this pro-
moter in cellular assays. To do this, we cloned the
ORR1A0 promoter upstream of a Firefly luciferase re-
porter gene in the pGL4.10[luc2] vector. This was then
co-transfected together with increasing amounts of
KLF1 in SL-2 cells, a cell line that is often used to exam-
ine KLF function due to minimal background CACCC-
binding activity [45]. We found that KLF1 strongly acti-
vates expression from the ORR1A0 promoter but has lit-
tle effect on empty pGL4.10[luc2] vector (Figure 4A). By
titrating increasing dosage of KLF3 we found that it
counters the activity of KLF1 at the ORR1A0 promoter
and represses expression (Figure 4B).
To investigate whether KLF1 indeed drives transcrip-
tion of these chimeric Pu.2 transcripts from the ORR1A0
element in vivo, we employed a KLF1-inducible eryth-
roid cell line known as B1.6 [56]. These cells were de-
rived from Klf1−/− fetal liver and have been rescued with
a transgene encoding a tamoxifen-inducible KLF1-ER
(estrogen receptor) fusion protein. Upon addition of
tamoxifen, KLF1-ER is activated and drives expression of
KLF1 target genes to induce hemoglobinization and
erythroid differentiation. KLF3 protein has not been de-
tected in these cells, although Klf3 mRNA is induced
after KLF1-ER activation [50].
Using real-time RT-PCR we observed a low level of
Pu.2 mRNA in untreated B1.6 cells; however, tamoxifen
induction resulted in a dramatic increase of these
transcripts (Figure 4C). Moreover, despite decreased ex-
pression of canonical Pu.1 transcripts upon KLF1-ER in-
duction (represented by exon 2/exon 3, Figure 4D), the
total level of Pu.1 plus Pu.2 transcripts increased (repre-
sented by the exon 3/exon 4 junction, Figure 4E), albeit
not significantly. This suggests that the chimeric tran-
scripts contribute substantially to the total Pu.1 plus
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Pu.2 mRNA pool in induced B1.6 cells. In addition, the
induction of Pu.2 expression was rapid following tam-
oxifen addition (within 2 hours) and occurred in the
presence of the translation inhibitor cycloheximide
(Additional file 3: Figure S3A, B). Taken together, these
data suggest that KLF1 directly activates Pu.2 transcrip-
tion from the endogenous ORR1A0 promoter in eryth-
roid cells in the absence of KLF3.
Widespread de-repression of chimeric transcripts from
ORR1A0 elements in the absence of KLF3
A RepeatMasker survey revealed that there are approxi-
mately 2,130 ORR1A0 integrants in the mouse genome.
The consensus sequence of ORR1A0 found in Repbase
contains all of the core promoter sequences shown in
Figure 2B as well as the four 5′-NCN CNC CCN-3′
motifs. In addition, there is little divergence between in-
dividual ORR1A0 elements with elements generally shar-
ing greater than 97% sequence identity to the consensus
[57]. We therefore hypothesized that KLF3 might play a
broader role in silencing aberrant transcription from
ORR1A0 LTRs.
To investigate this, we performed RNA-Seq on tripli-
cate samples of Klf3+/+ and Klf3−/− E14.5 TER119+ fetal
liver cells. In total, 1,025 genes were found to be signifi-
cantly deregulated (FDR <0.05) in the absence of KLF3
Figure 3 KLF1 and KLF3 bind to CACCC boxes in the ORR1A0 LTR. Nuclear extracts were harvested from COS cells expressing KLF3 (A, B)
and KLF1 (C, D) and were analyzed by EMSA using radiolabelled probes covering the four CACCC boxes in the ORR1A0 LTR promoter shown
in Figure 2b. Unbound DNA probes are indicated by *. KLF3:DNA and KLF1:DNA complexes are represented by ** and ***, respectively. The
identities of these complexes were confirmed by supershifting (****) with antibodies specific for KLF3 (A, B) and KLF1 (C, D). In (A and B), a
radiolabelled probe encompassing a known KLF3 binding site in the Fam132a promoter [54] has been included as a positive control. In (C and
D), a probe containing a CACCC-box from the β-major globin promoter, a site that is strongly bound by KLF1 [46], has been used as a positive
control. In (A and B), a background band present in mock-transfected COS cells co-migrates with KLF3, but at a much lower intensity and it does
not shift with the KLF3 antibody.
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(Additional file 4: Table S1). The majority of these
(76.7%) were upregulated in Klf3−/− cells, concordant
with the view from previous studies that KLF3 is pre-
dominantly a transcriptional repressor [49]. Importantly,
previously validated KLF3 targets also displayed signifi-
cant upregulation by RNA-Seq including Klf8 (108-fold),
Lgals3 (33-fold), Fam132a/adipolin (7.5-fold), Hba-x
(2.3-fold), and Hbb-y (1.8-fold) [49,50,54,58].
We next assessed whether the ORR1A0 LTR, and re-
lated ORR1A0-int, elements were enriched among the
list of KLF3 target genes. We found that of the 786 sig-
nificantly upregulated genes, 166 of these (21.1%) con-
tained one or more ORR1A0 LTRs. In contrast, of the
239 downregulated genes, there was only one instance of
an overlap with an ORR1A0 element (0.004%). Similarly,
ORR1A0-int elements, which are typically flanked by
ORR1A0 LTRs, were found in 96 upregulated genes
(12.2%) and only in a single case of a downregulated
gene. These results illustrate a clear enrichment of the
ORR1A0 and ORR1A0-int retroelements specifically
within genes that are normally repressed by KLF3 in
erythroid cells.
Because of sequence conservation between ORR1A0
elements and difficulties associated with unambiguously
assigning them to specific genomic loci, we instead
looked for evidence of splicing between ORR1A0 tran-
scripts and downstream genic exons. To do this, we con-
fined our analysis to annotated genes which displayed
differential isoform expression in Klf3−/− cells (greater
than 10-fold upregulated compared to Klf3+/+). We iden-
tified 70 such genes (Additional file 5: Table S2). Of
these, 34.3% contained transcribed ORR1A0 elements,
and almost half of these (41.7%) were spliced to genic
exons and a further 16.7% showed splicing to un-
annotated exons.
By real-time RT-PCR, we validated these results for a
selection of candidate target genes. Using forward
primers specific for the ORR1A0 exon and reverse
primers specific for downstream genic exons, we ob-
served striking upregulation for all three genes tested
Figure 4 KLF1 drives expression from the Pu.2 ORR1A0 promoter. (A, B) SL2 cells were co-transfected with pGL4.10 Firefly luciferase reporter
(promoter-less or containing the ORR1A0 promoter) together with increasing amounts of pPac-Klf1 (A) or a steady amount of pPac-Klf1 and
increasing dosage of pPac-Klf3 (B). Firefly levels have been normalized to Renilla luciferase and in each instance the lowest value has been set to
1.0. Charts represent the mean of triplicate experiments and error bars show standard error of the mean. *, P <0.005 (Student’s two-tailed t-test)
compared to pGL4.10-ORR1A0 wells transfected with 0 ng pPac-Klf1 (A) or 0 ng pPac-Klf3 (B). (C-E) KLF1-ER activity was induced in B1.6 cells
by addition of tamoxifen and total RNA was extracted after 48 h and analyzed by quantitative real-time RT-PCR. Transcripts containing exons
2b/3 are increased (C) while those containing exons 2/3 are decreased (D). The total pool of Pu.1 plus Pu.2 mRNA is represented by exons 3/4
(E). Values have been normalized to 18S rRNA and in each case, the lowest value has been set to 1.0. Error bars represent standard error of the
mean and n = 4 for each condition. **, P <0.05 (Student’s paired two-tailed t-test) compared to untreated cells.
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(Znrf2, Brca2, and Pqlc3) in E14.5 TER119+ cells lacking
KLF3 (Figure 5A, C, E), mirroring our previous result
for Pu.2 transcripts (Figure 2D). In addition, expression
of all of these chimeric mRNAs increased considerably
upon tamoxifen induction of B1.6 cells (Figure 5B, D, F).
In these cells, their upregulation was rapid (Additional
file 3: Figure S3C, E) and occurred in the presence of cy-
cloheximide (Additional file 3: Figure S3D, F), suggesting
that like Pu.2, their transcription is also directly driven
by KLF1. Lastly, it should be noted that definitively map-
ping repetitive reads to their correct genomic loci is dif-
ficult and thus the RNA-Seq analysis is not anticipated
to give an exhaustive list of genes for which ORR1A0
exons are spliced to downstream exons. Indeed, by tar-
geted real-time RT-PCR we assessed a further five candi-
date genes for which the RNA-Seq analysis had not
Figure 5 KLF1 activates while KLF3 represses chimeric transcripts from ORR1A0 LTRs in erythroid cells. RNA from Klf3+/+ (WT), Klf3+/− (HET),
and Klf3−/− (KO) TER119+ E14.5 fetal liver cells (A, C, E) and from untreated and tamoxifen-treated KLF1-ER inducible B1.6 cells (B, D, F) was analyzed
by quantitative real-time RT-PCR using forward primers which recognize the ORR1A0 exon and reverse primers specific for downstream exons of the
Znrf2 (A, B), Brca2 (C, D) and Pqlc3 (E, F) genes. All values have been normalized to 18S rRNA levels and WT (A, C, E) and untreated (B, D, F) samples
have been set to 1.0. Error bars represent standard error of the mean and n = 3 for each genotype or condition. *, P <0.05 (Student’s two-tailed t-test)
compared to both Klf3+/+ and Klf3+/− (A, C, E) and compared to untreated cells (B, D, F).
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Figure 6 (See legend on next page.)
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called splicing events (Cd59b, Tmx4, Bzw2, Cpe, and
Tcfl5). In each case, we found that in Klf3−/− cells, the
ORR1A0 exon is spliced and the resulting chimeric tran-
scripts are markedly upregulated compared to Klf3+/+
and Klf3+/− cells (Additional file 6: Figure S4A-C).
De-repressed transcription from ORR1A0 elements
was found to affect local gene expression in a number of
ways, shown in Figure 6 and Additional file 7: Figure S5.
In many instances, ORR1A0 LTRs reside within the body
of the gene and the new transcripts are spliced to down-
stream genic exons. This is the case for Pu.1, Thsd7b,
Znrf2, and Brca2 (Figure 6A, B, Additional file 7: Figure
S5A, B). In addition, ORR1A0 LTRs upstream of genes
also act as novel transcriptional start sites for such
chimeric transcripts, as is the case for Pqlc3 (Figure 6C).
We also observed spliced transcripts emanating from
ORR1A0 elements in un-annotated regions (Figure 6D)
and also detected novel transcripts antisense to known
genes (Additional file 7: Figure S5C). Lastly, in several
cases we observed significantly de-repressed transcription
from and across ORR1A0 elements that did not appear to
influence the expression of the surrounding gene, as for
Drosha (Additional file 7: Figure S5D). This typically oc-
curred either where two ORR1A0 LTRs exist as a cassette,
flanking an ORR1A0-int element (Additional file 7: Figure
S5D), or where they are in an antisense direction to a tran-
scribed gene (Additional file 7: Figure S5C).
Several of these chimeric transcripts have previously
been reported as ESTs that have typically been detected in
embryonic cells and tissues from a range of developmental
stages including 4-cell (Brca2; GenBank:CN716605) and
8-cell stage embryos (Chr10: chr10:61042355–61063209
shown in Figure 6D; GenBank:CJ067427), E13 liver tissue
(chr9:9049867–9081010; GenBank:CJ043932), and E17
amnion (Znrf2; GenBank: BY073363 and CJ093793). This
provides further evidence that ORR1A0 LTRs are capable
of functioning as bona fide promoters in vivo.
The chimeric Pu.2 transcript driven by the ORR1A0
promoter is translated in vivo
Thus far, the results presented here suggest that KLF3
silences aberrant transcription from ORR1A0 LTRs in
erythroid cells. These chimeric transcripts potentially
encode protein variants that might functionally impact
normal murine erythropoiesis. Indeed, Klf3 null mice ex-
hibit a number of erythroid defects including increased
immature red blood cells (reticulocytes) and nuclear in-
clusions (Howell-Jolly bodies) in peripheral blood [49].
We thus sought to determine whether these chimeric
transcripts are in fact translated in vivo using the Pu.1
gene as an example, given the role of this transcription
factor as a master regulator of hematopoietic differenti-
ation [59].
The chimeric Pu.2 transcript contains a potential ATG
start codon within exon 3 (Figure 2C) and is predicted
to encode a truncated isoform (PU.2) that lacks 88
amino acids at its N-terminus. Since the ETS DNA-
binding domain lies at the C-terminus of PU.1, we antic-
ipated that PU.2 would retain DNA-binding ability. We
cloned and expressed PU.1 and PU.2 in COS cells and
tested their ability to bind to a radiolabelled probe con-
taining the PU.1 DNA-binding consensus sequence (5′-
GAGGAA-3′) by EMSA. Indeed, PU.2 is able to bind to
DNA and migrates more rapidly than PU.1 (Figure 7A).
Moreover, while PU.1 is recognized and supershifted by
antibodies raised against both the N- and C-terminus of
PU.1, PU.2 is only supershifted by the antibody specific
for the C-terminus (Figure 7A).
To determine whether PU.2 protein is expressed in vivo,
we analyzed nuclear extracts from E14.5 Klf3−/− fetal
livers. Extracts from these cells formed bands that co-
migrated with both PU.1 and PU.2 (Figure 7A). The upper
band is supershifted by both antisera while the lower band
is only supershifted by the C-terminal antisera, confirming
their identities as PU.1 and PU.2, respectively (Figure 7B,
C). PU.2 protein was also detected in nuclear extracts
from Klf3+/+ fetal liver cells (Figure 7B, C) albeit at a lower
level than in Klf3−/− samples. Lastly, we also observed
marked induction of PU.2 protein upon tamoxifen activa-
tion of KLF1-ER in B1.6 cells (Figure 7D) consistent with
the upregulation of Pu.2 transcripts (Figure 4C). Taken to-
gether, these results indicate that PU.2 is indeed translated
in erythroid cells in vivo.
PU.2 can act as a dominant negative protein in
erythroid cells
The PU.2 protein lacks the N-terminal activation do-
main of PU.1, a region that interacts with the general
(See figure on previous page.)
Figure 6 RNA-Seq analysis of de-repressed chimeric transcripts in erythroid cells in the absence of KLF3. Tracks represent merged data
for triplicate Klf3+/+ (WT) and Klf3−/− (KO) E14.5 TER119+ fetal liver cell samples. Four loci are shown: the Pu.1/Sfpi1 gene (A), the Thsd7b gene (B),
the Pqlc3 gene (C), and a region on chromosome 10 (D). In each panel, sequencing reads are shown for WT (top) and KO (bottom). Within each
panel, the intensity scale is consistent for both genotypes and is shown on the left. Underneath the reads, detected splicing events are shown in
red (sense) or purple (anti-sense). Similarly, directionality of genes has been denoted as being on either the sense (+) or anti-sense (−) strand.
The positions of ORR1A0 and ORR1A0-int elements are shown at the bottom of each panel. In (A and B), internal ORR1A0s are transcribed and
spliced to downstream genic exons which show a marked increase in expression in KO samples. In (C), an ORR1A0 element serves as an upstream
promoter and transcripts are spliced to genic exons. In (D), an ORR1A0 is transcribed solely in KO cells and is spliced to unannotated exons.
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transcription factor TFIID [60]. We therefore postulated
that PU.2 might not function as a transcriptional activa-
tor and might antagonize the activity of PU.1 at its target
genes. To investigate this, we first conducted reporter
assays using the promoter of a previously characterized
PU.1 target gene, CLEC5A [61]. We found that while
PU.1 robustly activated expression, PU.2 repressed this
promoter in a dose-dependent manner (Additional file 8:
Figure S6A, B).
We next sought to examine the possible dominant
negative activity of PU.2 in a hematopoietic system. To
do this, we ectopically expressed PU.2, with or without
PU.1, in human K562 cells and derived stable clones
(Figure 8B, C). Forced expression of PU.1 has previously
been shown to promote monocytic differentiation of
these cells while inhibiting erythroid maturation [62].
Strikingly, we found that expression of PU.2, both by it-
self and when co-expressed with PU.1, caused spontan-
eous erythroid differentiation of these cells in the
absence of any chemical-inducing agents (Figure 8A).
Microarray analysis and real-time RT-PCR validation of
these cell lines confirmed the upregulation of multiple
erythroid genes including the globins, ALAS2, and
erythroblast membrane-associated protein (ERMAP)
(Additional file 9: Table S3, Figure 8D-G). These results
suggest that the LTR-driven PU.2 protein that is upregu-
lated in the absence of KLF3 can oppose the normal
function of PU.1 and promote erythroid differentiation.
Discussion
It has recently been shown that TEs frequently act as
promoters of genic transcription and are dynamically
transcribed during ontogeny [17,18,20,22]. Typically, the
majority of retroelement silencing occurs early in gesta-
tion [28] and numerous studies have demonstrated the
role of histone- and DNA-modifying enzymes in this
process [27,30-34,36]. KRAB domain zinc finger pro-
teins, which interact with the co-repressor TRIM28,
have been proposed to play a role in the specific recog-
nition and repression of distinct retroelement families
[31,35,37,39,40]. This has indeed shown to be the case
for ZFP809 in embryonic stem cells [38]. Other DNA-
binding zinc finger proteins, including REX1/ZFP42,
have also been implicated, but their mechanism of action
remains unclear and they appear to affect multiple, un-
related retroviral families [63].
Here we show that the zinc finger protein KLF3, which
lacks a KRAB domain, is required for the silencing
of transcription from ORR1A0 elements of the MaLR
family. In the absence of KLF3, there is a pronounced
increase in chimeric transcripts generated from these
LTRs. The phenomenon of deregulated chimeric tran-
scription has previously been observed upon ablation of
epigenetic modifiers such as SETDB1 and LSD1 in em-
bryonic stem cells [27,34]. For example, in cells lacking
SETDB1, 15% of de-repressed genes arise due to failed
silencing of promoter-proximal ERVs and half of these
genes exhibit chimeric transcripts [27]. However, in both
of these cases the effects described were more global
than we observe for KLF3 and covered diverse retroele-
ment families.
Silencing of the ORR1A0 LTR by KLF3 appears to
occur largely independently of the TRIM28/SETDB1
pathway and DNA methylation. Analysis of over 23,000
TRIM28 binding sites in ES cells compiled from two
studies [40,64] revealed that only eight lie within 100 bp
of an ORR1A0 element. This may partially reflect the
difficulties of detecting ChIP peaks that extend beyond
the boundaries of repeat elements. However, a separate
examination of regions of TRIM28-dependent H3K9 tri-
methylation, which typically spread beyond repeat borders,
revealed that only 62 of the 2,140 ORR1A0 LTRs (that is,
2.9%) lie within 100 bp [40]. Similarly, analysis of the
DNA methylation status of hematopoietic stem cells and
erythroblasts revealed that only 1.0% (22) and 0.3% (7) of
ORR1A0s, respectively, lie proximal to regions of DNA-
methylation as determined by MBD-Seq [65].
From a number of Klf3−/− tissues examined, the upreg-
ulation of ORR1A0 transcription appeared to be re-
stricted to erythroid cells. This is of particular interest
given that most retroelement silencing has been demon-
strated in embryonic stem and germ cells [27,30,31,33].
This suggests that KLF3 plays an active role in somatic
repression of retroviral transcription, both in fetal and
adult erythroid tissues. Consistent with its erythroid
restricted profile, we found that the master erythroid
(See figure on previous page.)
Figure 7 PU.2 is a LTR-driven novel isoform of PU.1 that retains DNA-binding activity. Nuclear extracts were analyzed by EMSA using a
radiolabelled probe containing the PU.1 DNA-binding consensus. (A) PU.1 and PU.2 expressed in COS cells co-migrate with bands observed in
Klf3−/− (KO) fetal liver nuclear extracts. PU.1 is supershifted by antibodies specific for the N-terminus and C-terminus, while PU.2 is only recognized
by the C-terminal antibody. Nuclear extracts from COS cells transfected with empty pMT3 vector have been included as a control. (B, C) In Klf3+/+
(WT) and Klf3−/− (KO) fetal liver nuclear extracts, the band which co-migrates with PU.1 is recognized by both antibodies while the band that
co-migrates with PU.2 is only supershifted by the C-terminal antibody, confirming the identities of the two bands. In (A-C), comparative
quantification of nuclear extract preparations was achieved by western blotting for β-actin. (D) Nuclear extracts from untreated and tamoxifen-
treated KLF1-ER inducible B1.6 cells. Nuclear extracts from COS cells transfected with PU.2 (and mock transfected) have been included as controls.
The identity of the PU.2 is confirmed by addition of the C-terminal antibody (αPU.2). In (A-D), supershifts have been indicated by arrows, and
additionally by an asterisk in (B).
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Figure 8 Forced expression of PU.2 in K562 cells induces spontaneous erythroid differentiation. (A) Cell pellets of K562 lines infected with
pMSCVpuro-Pu.1, pMSCVhyg-Pu.2, pMSCVpuro-Pu.1 plus pMSCVhyg-Pu.2, and empty vector (pMSCVpuro plus pMSCVhyg). Hemoglobinization
(signified by red hue) is apparent in the lines expressing PU.2 and PU.1 plus PU.2. (B-G) Total RNA was extracted from duplicate lines and was
subjected to quantitative real-time RT-PCR analysis using primers specific for: (B) the 5′ end (exon 2/3) of the murine Pu.1 gene (recognizes Pu.1
only and not Pu.2); (C) the 3′ end (exon 3/4) of Pu.1/Pu.2 (recognizes both Pu.1 and Pu.2); (D) ALAS2; (E) ζ-globin (HBZ); (F) ERMAP; and (G) δ-globin
(HBD). In (B and C) the duplicate lines have been shown separately while in (D-G) the average of the two lines has been determined. Levels have
been normalized to 18S rRNA and set to 1.0 for the lowest samples. Error bars represent standard error of the mean. *, P <0.05 (Student’s two-
tailed t-test) compared to empty vector.
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regulator KLF1 drives expression of ORR1A0-originating
transcripts in the absence of KLF3.
The specific recognition of the ORR1A0 element by
KLF3 and KLF1 appears to involve two 5′-CACNCCC-
3′ boxes upstream of the TSS (Figures 2B and 3). The
similar DNA-binding specificities of KLF1 and KLF3
have previously been noted and indeed, approximately
50% of KLF3 target genes in erythroid cells are also reg-
ulated by KLF1 [49]. Interestingly, the ORR1A0-related
LTR ORR1A1 lacks one of the 5′-CACNCCC-3′ boxes
and additionally lacks the TATA box. Despite being 97%
homologous with ORR1A0 and occurring at twice the
frequency in the mouse genome, we did not observe
enrichment of ORR1A1 in KLF3 repressed transcripts,
alluding to the functional importance of these two pro-
moter motifs and the extraordinary specificity of KLF3
for the ORR1A0 LTR.
Moreover, although the ORR1 retroelement family is
abundantly represented throughout diverse rodent spe-
cies, the ORR1A0 LTR is specifically only found in the
mouse. It is interesting to note that the DNA-binding
domain of KLF3 shows complete sequence conservation
between Mus musculus, Rattus norvegicus, and Homo
sapiens. This suggests that in the mouse, the DNA-
binding specificity of KLF3 has not altered in response
to the emergence of the ORR1A0 retroelement. Rather, it
appears that KLF3-mediated repression of ORR1A0 oc-
curred intrinsically from the initial appearance of the
retroelement, and in this context, the spread of the
ORR1A0 LTR may have been tolerated without deleteri-
ous impacts.
While KLF3 appears to efficiently silence ORR1A0
transcription in spleen and bone marrow cells, it is pos-
sible that at particular stages of development or cellular
maturation, KLF1 predominates and these chimeric
transcripts are expressed at higher levels, as observed in
the B1.6 erythroblast line. These chimeric transcripts po-
tentially encode functional protein isoforms and indeed,
in the case of the Pu.1 locus, we have detected a trun-
cated isoform expressed in fetal liver. PU.2 counters the
normal activity of PU.1 and instead promotes erythroid
differentiation when ectopically expressed in myeloid
leukemic K562 cells (Figure 8). This is consistent with
the role of its transcriptional activator, KLF1, in driving
terminal erythroid differentiation [44]. From this study,
we cannot discount the possibility that the chimeric
transcripts driven by KLF1 may be biologically func-
tional in some circumstances. Indeed, host exaptation of
TEs by exonization or through the remodelling of ex-
pression programs is a phenomenon of which multiple
instances have been described [5,13,14,19]. Incidentally,
although the consensus sequence of the ORR1A0 exon
contains a number of short open reading frames (see
Figure 2B), each ATG is ultimately succeeded by an in-
frame stop codon. Thus ORR1A0 promoters are pre-
dicted to drive expression of either full-length endogen-
ous proteins (where a canonical translation start site lies
in a downstream, spliced exon), or N-terminal truncated
protein isoforms, in cases where internal ATGs are suit-
able start sites of translation, as for PU.2.
The importance of appropriate retrotransposon con-
trol is apparent from numerous examples in which dys-
regulation results in disease [25,26]. It is unclear as to
the extent to which the dysregulation of ORR1A0 tran-
scription affects the physiology of the Klf3 null mice.
However, these animals do display an erythroid pheno-
type, with impaired maturation, reticulocytosis, increased
Howell-Jolly bodies and decreased lifespan of erythrocytes
[49]. These defects have not been attributed to any single
gene and it is more likely that they arise as a complicated
result of multiple defects including the widespread expres-
sion of aberrant, chimeric transcripts that we have pre-
sented here.
Conclusions
In summary, these findings emphasize the non-redundant
role that KLF3 plays in preventing widespread, promiscu-
ous transcription specifically from the ORR1A0 LTR. We
suggest that KLF3 is likely one of a patchwork of zinc fin-
ger proteins including ZFP809 that together collaborate to
silence the diverse collection of TEs that constitute such a
large fraction of vertebrate genomes.
Materials and methods
Klf3−/− mice
Generation and maintenance of the Klf3−/− mouse line
has been described previously [66]. Ethical approval for
animal use was obtained from the appropriate Animal
Care and Ethics Committees (University of Sydney, ap-
proval number L02/7-2009/3/5079; and University of
New South Wales, approval number 09/128A). Genomic
DNA was extracted from tail snips using DirectPCR
Lysis Reagent (Viagen Biotech Inc, Los Angeles, CA,
USA) as per the manufacturer’s instructions and geno-
typing was performed as described previously [66].
Sorting of TER119+ fetal liver cells
TER119+ cells were sorted from whole fetal livers (E13.5
or E14.5) using anti-TER119 Microbeads with MS or LS
columns (Miltenyi Biotec Australia, North Ryde, NSW,
Australia) as per the manufacturer’s protocol. After eluting,
cells were centrifuged at 300 g for 10 min at 4°C and RNA
was extracted from the cell pellet as described below.
RNA extraction and quantitative real-time RT-PCR
RNA was extracted, purified and subjected to DNase
treatment as described previously [45,49]. Extracted
RNA was then used as a template for cDNA synthesis
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using the SuperScript® VILO™ cDNA Synthesis Kit (Invi-
trogen, Carlsbad, CA, USA) as instructed by the sup-
plier. Quantitative real-time RT-PCR reactions were
set up as described previously [45,49] but using Fas-
tStart Universal SYBR Green Master (ROX) (Roche
Diagnostics Australia Pty Ltd, Castle Hill, NSW,
Australia) or Power SYBR® Green PCR Master Mix
(Life Technologies, Gladesville, NSW, Australia). Re-
actions were run using the Applied Biosystems 7500
Fast Real-Time PCR System (Life Technologies) and
data were analyzed using 7500 Software v2.0.4 (Life
Technologies). Relative quantification was calculated
using 18S rRNA levels and standard curves derived
from serial dilutions of amplicon as described previ-
ously [45].
Real-time RT-PCR primers
Gene-specific primer pairs were designed using the
Primer-BLAST tool [67] or PrimerExpress v3.0 (Applied
Biosystems, Foster City, CA, USA) software to cross
exon boundaries where possible. Primers were included
in reactions at a concentration of 400 nM. The se-
quences of forward and reverse primers for each gene
are: 18S, 5′-CACGGCCGGTACAGTGAAAC-3′ and
5′-AGAGGAGCGAGCGACCAA-3′; Pu.1 exons 2/3,
5′-CCTTCGTGGGCAGCGATGGA-3′ and 5′-GAGCT
GCTGTAGCTGCGGGG-3′; Pu.1 exons 3/4, 5′-GAG
CTGGAACAGATGCACGTCCT-3′ and 5′-GTGGGCT
GGGGACAAGGTTTGAT-3′; Pu.1 exons 4/5, 5′-TGG
AGAAGCTGATGGCTTGGAGC-3′ and 5′-CAGCA






















and ERMAP, 5′-GCTGTCTGTGCATGTGTCAG-3′ and
5′-CCACCTCACCTCCTTGGGTA-3′.
5′ RACE (Rapid Amplification of cDNA Ends)
600 ng total RNA from TER119+ fetal liver cells ob-
tained from Klf3+/+ and Klf3−/− embryos (E13.5) was
used as a template for first strand cDNA synthesis
using the SMARTer™ RACE cDNA Amplification Kit
(Clontech, Mountain View, CA, USA). The RACE PCR
was performed as directed by the supplier but using
0.05 unit/μL REDTaq DNA Polymerase (Sigma Al-
drich, St Louis, MO, USA). Thermal cycler settings
were 24 cycles of 94°C/30 s, 64°C/30 s, and 72°C/
1 min. Amplified products were resolved by electro-
phoresis through a 1.2% agarose gel and were purified
using the Wizard SV Gel and PCR Clean-up System
(Promega Corporation, Madison, WI, USA) as per the
manufacturer’s manual. Nested RACE PCR was then
performed as described above with slight alterations
to the thermal cycler parameters: 24 cycles of 94°C/
30 s, 60°C/30 s, and 72°C/1 min. First round and
nested RACE PCR primers are listed respectively: re-
verse primer targeting exon 4 of Pu.1, 5′-GTGGG
CTGGGGACAAGGTTTGAT-3′; reverse primer tar-
geting exon 3 of Pu.1, 5′- GCTGTAGCTGCGGGGG
CTGCACACT-3′. Amplicons were resolved and puri-
fied as described above and were sequenced by the
Australian Genome Research Facility Ltd, Brisbane,
QLD, Australia.
Chromatin immunoprecipitation (ChIP)
ChIP was performed with slight modifications based on
Schmidt et al. [68]. Briefly, one cross-linked E14.5 liver
was used per IP with antibodies as follows: IgG, 5 μg sc-
2027 (Santa Cruz Biotechnology, Santa Cruz, CA, USA);
anti-H3K4me3, 5 μg C42D8 (Cell Signaling Technology,
Danvers, MA, USA), or 5 μg ab12209 (abcam, Cambridge,
MA, USA); anti-H3K9me3, 5 μg ab8898 (abcam); anti-
H3K27me3, 3 μg C36B11 (Cell Signaling Technology) or
5 μg ab6002 (abcam); anti-H3K27ac, 0.5 μg #4353 (Cell
Signaling Technology) or 5 μg ab4729 (abcam). Real-time
PCR quantification of chromatin pull-down was per-
formed as described above and amounts were normalized
to the level of input material prior to immunoprecipita-
tion. ChIP primer sequences have been described previ-
ously for Klf8 promoter 1a and Fam132a [49,50]. Other
primers used are as follows: Pu.2 ORR1A0 -250 bp, 5′-G
AAGTCCTTCTGGCTTCTGCAT-3′ and 5′-CTGACCT





and 5′-CTGGCAGCTCTCACCTCTCT-3′, and; Gapdh,
5′-GACAGTCGGAAACTGGGAAG-3′ and 5′-CATCAC
GTCCTCCATCATCC-3′. Base positions refer to where
amplicons are centered relative to the TSS.
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Vectors and cloning of PU.1 and PU.2
The vectors pPac and pPac-Klf1 were provided by Menie
Merika and Stuart Orkin (Harvard Medical School, Boston,
MA, USA). The plasmid pPac-Klf3 and the mammalian
expression vectors pMT3 and pMT3-Klf3 were gifts from
Dr José Perdomo (St George Clinical School, Sydney,
Australia). The mammalian expression vector pSG5-Klf1
was supplied by James Bieker (Mount Sinai School of
Medicine, New York, NY, USA). Firefly and Renilla lucifer-
ase vectors used were pGL4.10[luc2], and pGL4.23[luc2/
minP] and pGL4.74[hRluc/TK] as transfection controls
(Promega Corporation). The vector pEF-IRES-puro5
(pEF1α) was kindly provided by Dr Daniel Peet (University
of Adelaide, Adelaide, Australia). The Renilla luciferase re-
porter construct pLightSwitch-Clec5a, containing approxi-
mately 1.1 kb of the human CLEC5A promoter, was
purchased from Switchgear Genomics (Menlo Park, CA,
USA). The Pu.2 ORR1A0 promoter (−140 to +23) was syn-
thesized by GeneArt® (Life Technologies) and subcloned
into KpnI/XhoI pGL4.10[luc2] to create pGL4.10-ORR1A0.
Full length Pu.1 and Pu.2 were cloned from the cDNA
generated during the 5’′ RACE described above. PCRs
were set up using Phusion High-Fidelity DNA Polymer-
ase (Finnzymes OY, Espoo, Finland) as directed by the
supplier. Primers used in the first round of amplification
include: 10x Universal Primer A Mix (UPM) supplied
from SMARTer™ RACE cDNA Amplification Kit (Clon-
tech) as a forward primer, and a reverse primer specific
for exon 5 of Pu.1; 5′-TCCGGGCCGGGCGACGGGT-
TAATGCTAT-3′. Thermal cycler parameters were 98°C/
30 s, followed by 25 cycles of 98°C/10 s, 59°C/30 s, and
72°C/1 min, and a final cycle of 72°C/5 min. Amplified
Pu.1 and Pu.2 products were resolved by electrophoresis,
purified as described above and subjected to nested PCR
using foward primers covering the start points of trans-
lation for PU.1 (5′-ATTACTCGAGGCTCAGCTGGAT
GTTACAGGCGTGCAAA-3′) and PU.2 (5′-ATTACT
CGAGGCCACCATGGAGCTGGAACAGATGCAC-3′)
together with the common reverse primer 5′-TAATGA
ATTCAGCCTGGCGGTCTCTGCGGGCGATCAGT-3′
(which includes the Pu.1 stop codon in exon 5). Param-
eter settings were 98°C/30 s, followed by 25 cycles of
98°C/10 s, 69°C/30 s, and 72°C/1 min, and a final cycle
of 72°C/5 min. The fragments were subsequently cloned
into XhoI/EcoRI pMT3 to form pMT3-Pu.1 and pMT3-
Pu.2, respectively. Pu.1 and Pu.2 were then subcloned into
XhoI/EcoRI pEF1α to generate pEF1α-Pu.1 and pEF1α-
Pu.2. Similarly, Pu.1 and Pu.2 were cloned into BglII/HpaI
pMSCVpuro and pMSCVhyg (Clontech), respectively,
using the forward primers 5′-ATTAAGATCTGCTCA
GCTGGATGTTACAGGCGTGCAAA-3′ and 5′- ATTA
AGATCTGCCACCATGGAGCTGGAACAGATGCAC -3′
and the reverse primer 5′-TAATGTTAACAGCCTGGC
GGTCTCTGCGGGCGATCAGT-3′.
Cell culture
COS cells were cultured as described previously [45].
K562 and HL60 cells were maintained similarly but in
RPMI 1640 culture medium (Gibco-BRL Life Technolo-
gies, Grand Island, NY, USA). Culture conditions for
B1.6 erythroblast cells have been described elsewhere
[56]. B1.6 cells were induced with tamoxifen as de-
scribed previously [45] and, with the exception of the
time-course and cycloheximide experiments, were har-
vested for RNA or nuclear extracts after 48 h. SL2
cells were cultured in Schneider’s Drosophila medium
(Gibco-BRL Life Technologies, Grand Island, NY, USA)
supplemented with 10% heat-inactivated FCS and 1%
penicillin/streptomycin/glutamine solution at 24°C.
Transfections and retroviral infections
COS cells were transfected with 5 μg pMT3-Pu.1, pMT3-
Pu.2 or pMT3 empty using FuGENE6 (Roche Diagnostics)
as instructed by the supplier. Cells were harvested after
48 h for nuclear extracts. For retroviral infection of K562
cells, Phoenix A packaging cells were transfected with
12 μg total vector DNA (12 μg pMSCVpuro-Pu.1, 12 μg
pMSCVhyg-Pu.2, 6 μg pMSCVpuro plus 6 μg pMSCVhyg,
or 6 μg pMSCVpuro-Pu.1 plus 6 μg pMSCVhyg-Pu.2)
using Lipofectamine 2000 (Life Technologies) according
to the manufacturer’s instructions. Target K562 cells were
seeded at 1 × 105 cells/mL in 6-well Plates 24 h prior to
infection. Forty-eight hours following infection of pack-
aging cells, virus-containing media (VCM) were collected
and passed through a 0.45 μm low protein binding filter.
Non-tissue culture treated 6-well dishes were then coated
with RetroNectin® (Clontech) as instructed by the manu-
facturer. Half the volume of VCM was then added to the
6-well dishes for 30 min at room temperature. The target
K562 cells were resuspended in the remaining VCM
with the addition of protamine to a final concentration of
8 μg/mL. After 30 min, the VCM was aspirated from the
coated wells and was seeded with the K562 cells. The
plates were subsequently centrifuged at 400 g for 1.5 h at
30°C and then incubated at 37°C with 5% CO2 overnight.
After 12 h, VCM was collected from the packaging cells
for a second round of infection as described above. Eight
hours after the second spinoculation, the K562 cells were
replenished with additional VCM and incubated for 48 h
before replating in RPMI 1640 culture medium with 10%
(v/v) heat-inactivated FCS (Gibco) and 1% (v/v) penicillin/
streptomycin/glutamine solution (Gibco). After another
48 h, cells were subjected to antibiotic selection and main-
tained in 1 μg/mL puromycin dihydrochloride (Sigma)
and 200 μg/mL hygromycin B (Life Technologies) as
appropriate.
Separately, K562 cells were also transfected with
pEF1α-Pu.2 or pEF1α empty using the Gene Pulser Xcell
electroporation system (Bio-Rad, Hercules, CA, USA).
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Briefly, 106 cells and 20 μg plasmid were resuspended in
Dulbecco’s modified eagle medium (DMEM) low glucose
(LG) (Gibco-BRL Life Technologies) without serum and
in a total volume of 400 μL. Cells were electroporated
at 200 V, 950 μF and subsequently cultured and main-
tained in 2 μg/mL puromycin dihydrochloride to gene-
rate monoclonal lines.
Nuclear extracts and electrophoretic mobility shift assays
(EMSAs)
Nuclear extracts were obtained and EMSAs were per-
formed as described previously [46]. The radiolabelled
probe containing the PU.1 consensus binding site
comprises sense and antisense oligonucleotides for the
sequence 5′-GCTCGAGGACTTCCTCTTTCCAGTGC-
3′ as described elsewhere [69]. ORR1A0 double stranded




TCACCCTAGTTG-3′. The positive control KLF3 bin-
ding site in the Fam132a promoter is ‘Probe C’ from
[54]. The antibodies used that were specific for the
N-terminus and C-terminus of Pu.1 were 9G7 (Cell Sig-
naling Technology) and T-21 (Santa Cruz Biotechnol-
ogy), respectively. KLF1- and KLF3-specific antisera have
been described previously [46].
Western blotting
Western blots were performed by standard methods.
Briefly, nuclear extracts were separated by SDS-PAGE
and were electrotransferred to PVDF membrane, which
was then blocked with 5% skim milk in 50 mM Tris–
HCl (pH 7.4), 150 mM NaCl, and 0.05% Tween 20. PU.2
protein was probed by overnight incubation of mem-
brane in 5% skim milk with 0.2 μg/mL PU.1 antibody
(T-21) (Santa Cruz Biotechnology) at 4°C. Detection was
achieved using Immobilon Western Chemiluminescent
HRP Substrate (Millipore Corporation, Billerica, MA,
USA) and subsequently, membranes were stripped in
0.2 M NaOH for 10 min and were probed with β-actin
antibody (Sigma).
Reporter assays
SL2 cells were split into 6-well plates at a concentration
of 5 × 105/mL and 24 h later were transfected with
pPac-Klf1 (0, 50, or 250 ng) and pPac-Klf3 (0, 12.5, 25,
50, or 100 ng) supplemented to equal loads with pPac
empty vector, together with 100 ng pGL4.74 [hRLuc/TK]
and 1 μg pGL4.10 [luc2] or pGL4.10-ORR1A0 using
FuGene6 (Roche Diagnostics) as instructed by the sup-
plier. In competition assays, the pGL4.10-ORR1A0 vec-
tor (and pGL4.10 [luc2]) were driven by co-transfection
of 200 ng pPac-Klf1. After 48 h, cells were harvested and
lysates analyzed using the Dual-luciferase® Reporter Assay
System (Promega Corporation) and a TD20/20 lumin-
ometer (Turner Biosystems, Sunnyvale, CA, USA). HEK293
cells were similarly transfected but with 0, 10, 100, and
1,000 ng pEF1α-Pu.1 (supplemented with pEF1α to a total
of 1,000 ng vector) together with 1 μg pLightSwitch
(empty vector) or pLightSwitch-Clec5a. As a control,
100 ng pGL4.23 [luc2/minP] Firefly luciferase vector was
co-transfected. In competition assays, HEK293 cells were
transfected and analyzed as above but with 1 μg pEF1α-
Pu.1 together with 0, 10, 100 and 1,000 ng pEF1α-Pu.2.
Microarrays
Microarray data from TER119+ E14.5 fetal liver cells
from Klf3+/+ and Klf3−/− embryos have previously been
described [49]. Monoclonal K562 cell lines stably trans-
fected with pEF1α or pEF1α-Pu.2 (n = 3 each) were har-
vested for total RNA which was subsequently hybridized
to Affymetrix Human Gene 1.0 ST arrays according
to the manufacturer’s instructions (Affymetrix, Santa
Clara, CA, USA). Hybridization and processing were
performed by the Ramaciotti Centre for Gene Function
Analysis (University of New South Wales, Sydney,
Australia). Data were analyzed using Affymetrix® Expres-
sion Console™ software (Affymetrix). Microarray data are
available in the Gene Expression Omnibus database [70]
under accession number GSE50083.
High throughput RNA-sequencing (RNA-Seq)
RNA was extracted from TER119+-sorted liver cells
from three Klf3+/+ and three Klf3−/− litter-matched E14.5
embryos (two litters total). Libraries were prepared using
1 μg total RNA using the TruSeq RNA Sample Prep Kit
v2 (Illumina, San Diego, CA, USA) according to the
manufacturer’s instructions. The six libraries were multi-
plexed into two lanes using sample specific adapters
such that there were three samples per lane. 100 bp
paired end reads were sequenced using TruSeq v3 SBS
reagents on the Hiseq 2000 (Illumina, San Diego, CA,
USA). Library preparation and sequencing were per-
formed by the Ramaciotti Centre, University of New
South Wales, New South Wales, Australia. Quality con-
trol on the reads was performed using FastQC v0.10.1
available from [71].
Two separate strategies were used for alignment and
RNA-seq analysis. The first of these sought to uniquely
map reads from repeat elements by using high strin-
gency alignment cut-offs and was primarily employed to
visualize chimeric splicing events using Integrative
Genomics Viewer [72]. Reads were aligned to the mm10
Mus musculus genome using tophat2 (v2.0.4) using the
default settings except for the following (-r -40 --segment-
length 50 --coverage-search --segment-mismatches 0 -g
50 --genome-read-mismatches 0 --read-mismatches 0 -I
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200000 --no-discordant --no-mixed --b2-L 30 --b2-D
10000 --b2-R 100 -n 0 -M) [73]. The second approach
used more relaxed cutoffs to better measure expression
levels of non-repeat exons. This latter approach was
employed to determine differential gene and isoform
expression (Additional file 4: Tables S1 and Additional
file 5: Table S2). Again, reads were aligned to the mm10
Mus musculus genome using the default settings of tophat2
(v2.0.4), except for the following (--no-discordant -M --no-
coverage-search --microexon-search -n 3 --genome-read-
mismatches 3 --read-mismatches 3 --b2-sensitive -G) [73].
Transcripts were assembled using Cufflinks v2.0.2 and
the mm10 annotations were included [74]. Transcripts
across all replicates were merged using cuffmerge and
differential expression analysis was performed pair-wise
on the groups using cuffdiff. A q-value (FDR) threshold
of <0.05 was used to determine significantly differentially
expressed genes. RNA-Seq data have been deposited in
the Gene Expression Omnibus under the accession num-
ber GSE50554.
Bioinformatics
The sequence and genomic positions of ORR1A0 LTR
elements were determined using the RepeatMasker
program [75] in conjunction with the University of
California Santa Cruz (UCSC) Genome Browser [76].
Sequence information of retroelement families was
obtained using Repbase Update [57,77]. The overlap
between differentially expressed loci as measured by
RNA-Seq and ORR1A0 and ORR1A0-int elements was
established using the intersect command in Bedtools
v2.17.0 [78]. Similarly, overlaps (using 100 bp windows)
were determined between ORR1A0 elements and: TRIM
28 ChIP peaks (from [40,64]); TRIM28-dependent
H3K9me3 peaks (from [40]), and regions of DNA
methylation in hematopoietic stem cells and erythro-
blasts (from [65]). Gene Expression Omnibus accession
numbers for the data sets analyzed are GSM1032198,
GSM773067, GSM1032190, and GSE38354, respectively.
Additional files
Description of additional files
The following additional data are available with the on-
line version of this paper. Additional file 1: Figure S1
shows that the chimeric Pu.1 transcript (Pu.2) is pre-
dominantly upregulated in erythroid tissues in the ab-
sence of KLF3. Additional file 2: Figure S2 shows levels
of H3K9 tri-methylation at the Pu.2 promoter in Klf3−/−
and wild-type E14.5 fetal liver cells. Additional file 3:
Figure S3 shows that Pu.2 and other ORR1A0 chimeric
transcripts are rapidly activated by KLF1 and in the
presence of cycloheximide, suggesting that they are dir-
ect targets. Additional file 6: Figure S4 provides valid-
ation of genes to which the ORR1A0 exon is spliced in
Klf3−/− E14.5 TER119+ fetal liver cells. Additional file 7:
Figure S5 gives further examples of de-repressed ORR1A0
transcripts in the absence of KLF3. Additional file 8:
Figure S6 contains reporter assay data demonstrating the
opposing transcriptional activities of PU.1 and PU.2.
Additional file 4: Table S1 shows the list of genes that are
significantly, differentially expressed in Klf3−/− TER119+
fetal liver cells by RNA-Seq. Additional file 5: Table S2
shows the list of genes that have significantly de-repressed
isoforms. Additional file 9: Table S3 shows microarray re-
sults from K562 cell stably expressing PU.2.
Additional file 1: Figure S1. The chimeric Pu.1 transcript (Pu.2) is
predominantly upregulated in erythroid tissues in the absence of KLF3.
Total RNA was extracted from adult tissue from three Klf3+/+ (WT) and
three Klf3−/− (KO) mice and analyzed by quantitative real-time RT-PCR
using primers specific for the exon 2b/3 junction (A) or exon 2/3 junction
(B) of Pu.1. Levels have been normalized to 18S rRNA and the lowest
detectable reading in each chart has been set to 1.0. Error bars represent
standard error of the mean. *, P <0.05 (Student’s two-tailed t-test)
compared to wild-type.
Additional file 2: Figure S2. The relative enrichment of H3K9me3 at
the Pu.2 promoter in Klf3+/+ and Klf3−/− E14.5 fetal liver cells. ChIP data have
been expressed as percentage input for each locus (n = 2 for each IP for
Klf3+/+ (WT) or Klf3−/− (Klf3 KO)). Error bars represent standard error of the
mean. The Pu.2 promoter shows a moderate level of H3K9 tri-methylation
relative to positive (Serpina9) and negative (Gapdh) control loci.
Additional file 3: Figure S3. Pu.2 and ORR1A0 chimeric transcripts are
induced rapidly by KLF1-ER and in the presence of cycloheximide. RNA
from KLF1-ER inducible B1.6 erythroblast cells was analyzed by qRT-PCR
using primers specific for Pu.2 (A, B), ORR1A0-Znrf2 (C, D), and ORR1A0-
Brca2 (E, F). In (A, C, and E), RNA was harvested at 0, 2, 4, 8, and 24 h
following tamoxifen treatment (n = 2). In (B, D, and F), cells were treated
with cycloheximide for 30 min prior to tamoxifen addition (or ethanol
for untreated), with samples being taken 8 h thereafter (n = 4 for each
condition). All values have been normalized to 18S rRNA levels and
t = 0 h time points (A, C, and E) and tamoxifen-untreated samples
(B, D, and F) have been set to 1.0. Error bars represent standard error
of the mean. *, P <0.05 (Student’s one-tailed t-test) compared to t = 0 h
(A, C, and E) and tamoxifen-untreated (B, D, and F). N.S, not significant.
Additional file 4: Table S1. Genes that are significantly, differentially
expressed in Klf3−/− TER119+ fetal liver cells compared to Klf3+/+. RNA-Seq
was performed on triplicate samples and differentially expressed genes
were determined using a FDR cutoff of 0.05.
Additional file 5: Table S2. The list of annotated genes which have
significantly de-repressed isoforms (>10-fold) in Klf3−/− TER119+ fetal liver
cells compared to Klf3+/+. Eighty eight differentially expressed isoforms
(FDR <0.05) were determined, covering 70 different genes.
Additional file 6: Figure S4. Confirmation of further ORR1A0 splicing
events in Klf3−/− erythroid cells that were not detected by RNA-Seq
analysis. RNA from Klf3+/+ (WT), Klf3+/− (HET), and Klf3−/− (KO) TER119+
E14.5 fetal liver cells were analyzed by real-time RT-PCR using forward
primers specific for ORR1A0 and reverse primers recognizing downstream
exons of the Cd59b (A), Tmx4 (B), and Bzw2, Cpe, and Tcfl5 (C) genes.
(A and B) Values have been normalized to 18S rRNA levels and WT
samples have been set to 1.0. Error bars represent standard error of the
mean (n = 2 WT, 3 HET, and 3 KO). *, P <0.05 (Student’s two-tailed t-test)
compared to both Klf3+/+ and Klf3+/−. (C) For these genes, the spliced
transcripts were below the level of detection in Klf3+/+ cells and thus
could not be quantified. RT-PCR products were electrophoresed on
a 3% agarose gel and stained with ethidium bromide.
Additional file 7: Figure S5. Further examples of de-repressed ORR1A0
transcripts in the absence of KLF3. As in Figure 6, tracks represent RNA-Seq
reads and splicing events for Klf3+/+ (WT) and Klf3−/− (KO) E14.5 TER119+ fetal
liver cell samples. (A, B) ORR1A0 elements are transcribed and spliced to
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downstream exons of Znrf2 (A) and Brca2 (B), which in turn are expressed
at a significantly higher level in KO cells. (C) Spliced transcripts initiating
nearby to an ORR1A0 LTR are antisense to an annotated gene (Dhx57).
(D) De-repressed transcription of an ORR1A0/ORR1A0-int cassette does
not alter the expression of the surrounding gene (Drosha).
Additional file 8: Figure S6. PU.2 opposes the transcriptional activity
of PU.1. HEK293 cells were transfected with pLightSwitch Renilla luciferase
reporter vector (promoter-less or containing the CLEC5A promoter). In
(A), increasing amounts of pEF1α-Pu.1 have been co-transfected, while in
(B), a steady amount of pEF1α-Pu.1 has been co-transfected together
with increasing doses of pEF1α-Pu.2. In all experiments, pGL4.23[luc2/
minP] Firefly luciferase vector was included as a transfection control and
used for normalization. The means of triplicate experiments are shown
and error bars represent standard error of the mean. *, P <0.05 (Student’s
two-tailed t-test) compared to pLightSwitch-Clec5a wells transfected with
0 ng pEF1α-Pu.1 (A) or 0 ng pEF1α-Pu.2 (B).
Additional file 9: Table S3. Erythroid genes are upregulated upon
forced expression of PU.2 in K562 cells. Microarrays were performed on
monoclonal K562 cell lines stably transfected with pEF1α-Pu.2 or pEF1α.
A selection of erythroid genes that are upregulated >2-fold in cells
expressing PU.2 is shown.
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